Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Elixia PHC LLC

Neither a doctor nor a teaching hospital

Research payments

$975,786

12 payments

Through program year 2025, Elixia PHC LLC is reported as receiving $975,786 in research payments, across 12 payments.

By program year

3 rows
Year Kind Amount Payments
2025 Research $139,983 3
2024 Research $368,909 7
2023 Research $466,893 2

Breakdown

Who paid Research payments · program years 2023–2025
  1. AstraZeneca UK Limited $508,421 3 payments
  2. Boehringer Ingelheim Pharmaceuticals, Inc. $270,408 2 payments
  3. AstraZeneca Pharmaceuticals LP $139,368 2 payments
  4. Eli Lilly and Company $39,489 2 payments
  5. Chiesi USA, Inc. $18,100 3 payments
Studies the money was for Research payments · program years 2023–2025
  1. A Phase I-III Randomized Double blind Study to Evaluate the Safety and Neutralizing Activity of AZD5156-AZD3152 for Pre exposure Prophylaxis of COVID 19 in Participants with Conditions Causing Immune Impairment $508,421 3 payments
  2. PoCC study in patients with PTSD $270,408 2 payments
  3. A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease THARROS $139,368 2 payments
  4. The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (Surpass Cvot) $39,489 2 payments
  5. A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp 500g) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR) (PILLAR) $17,300 2 payments
  6. A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp 500g) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR) (PILLAR) $800 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record